Table 3.
Comparison of available drugs for antifungal treatment in Italy
| Overall (n = 49) | GDP | |||||
|---|---|---|---|---|---|---|
| < 30,000 € (n = 19) | > 30,000 € (n = 30) | |||||
| n | % | n | % | n | % | |
| Available antifungals | ||||||
| Amphotericin B | 44 | 89.8 | 18 | 94.7 | 26 | 86.7 |
| Deoxycholate | 9 | 18.4 | 1 | 5.3 | 8 | 26.7 |
| Lipid complex | 15 | 30.6 | 6 | 31.6 | 9 | 30.0 |
| Liposomal | 43 | 87.8 | 17 | 89.5 | 26 | 86.7 |
| Echinocandins | 45 | 91.8 | 18 | 94.7 | 27 | 90.0 |
| Anidulafungin | 36 | 73.5 | 15 | 78.9 | 21 | 70.0 |
| Caspofungin | 36 | 73.5 | 13 | 68.4 | 23 | 76.7 |
| Micafungin | 45 | 91.8 | 18 | 94.7 | 27 | 90.0 |
| Triazoles | 45 | 91.8 | 18 | 94.7 | 27 | 90.0 |
| Fluconazole | 45 | 91.8 | 18 | 94.7 | 27 | 90.0 |
| Isavuconazole | 39 | 79.6 | 16 | 84.2 | 23 | 76.7 |
| Itraconazole | 44 | 89.8 | 18 | 94.7 | 26 | 86.7 |
| Posaconazole | 41 | 83.7 | 18 | 94.7 | 23 | 76.7 |
| Voriconazole | 44 | 89.8 | 17 | 89.5 | 27 | 90.0 |
| Flucytosine | 24 | 49.0 | 11 | 57.9 | 13 | 43.3 |
| Terbinafine | 7 | 14.3 | 2 | 10.5 | 5 | 16.7 |
| Therapeutic drug monitoring | 31 | 63.3 | 7 | 36.8 | 24 | 80.0* |
| Flucytosine | 6 | 12.2 | 1 | 5.3 | 5 | 16.7 |
| Onsite | 5 | 10.2 | 1 | 5.3 | 4 | 13.3 |
| Outsourced | 1 | 2.0 | 0 | 0.0 | 1 | 3.3 |
| Itraconazole | 14 | 28.6 | 3 | 15.8 | 11 | 36.7 |
| Onsite | 10 | 20.4 | 2 | 10.5 | 8 | 26.7 |
| Outsourced | 4 | 8.2 | 1 | 5.3 | 3 | 10.0 |
| Posaconazole | 22 | 44.9 | 3 | 15.8 | 19 | 63.3* |
| Onsite | 16 | 32.7 | 2 | 10.5 | 14 | 46.7 |
| Outsourced | 6 | 12.2 | 1 | 5.3 | 5 | 16.7 |
| Voriconazole | 31 | 63.3 | 7 | 36.8 | 24 | 80.0** |
| Onsite | 23 | 46.9 | 6 | 31.6 | 17 | 56.7 |
| Outsourced | 8 | 16.3 | 1 | 5.3 | 7 | 23.3 |
GDP gross domestic product, US$ United States dollar
*This difference was considered as statistically significance, p = 0.005
**This difference was considered as statistically significance, p < 0.001